Posted by Michael Wonder on 09 May 2025
Adagrasib for previously treated patients with advanced KRAS G12C mutation positive non-small-cell lung cancer
9 May 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of adagrasib in the NHS in England.
For the time being, adagrasib should not be used to treat adults with advanced KRAS G12C mutation positive non-small-cell lung cancer whose cancer has progressed after, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1 or anti-PD-L1 immunotherapy.
